Directors & Officers

Dr. Steve Slilaty

Chairman & CEO

Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona. He is currently President & CEO of Sunshine Biopharma and has an appointment as Adjunct Professor at Universite du Quebec. Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks. His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 3.4.21.88) and the development of key technology for the Human Genome Project (TrueBlue Cloning System). With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap. At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of ground breaking drugs for the treatment of aggressive forms of cancer.


Mr. Camille Sebaaly, ENG.

Director & CFO

Mr. Sebaaly has over 20 years of experience in engineering, development and commercialization of emerging technologies worldwide. Mr. Sebaaly was appointed as our Chief Financial Officer, Secretary and a Director of our Company on October 15, 2009. Since 2001, Mr. Sebaaly has been self-employed as a business consultant, primarily in the biotechnology and biopharmaceutical sectors. He held a number of senior executive positions in various areas including, financial management, business development, project management and finance. As an executive and an entrepreneur, he combines expertise in strategic planning and finance with strong skills in business development and deal structure and negotiations. In addition, Mr. Sebaaly worked in operations, general management, investor relations, marketing and business development with emphasis on international business and marketing of advanced technologies including hydrogen generation and energy saving. In the area of marketing, Mr. Sebaaly has evaluated market demands and opportunities, created strategic marketing and business development plans, designed marketing communications and launched market penetration programs. Mr. Sebaaly was a cofounder of Advanomics Corporation with Dr. Slilaty. Mr. Sebaaly graduated from State University of New York at Buffalo with an Electrical and Computer Engineering Degree in 1987.


Dr. Abderrazzak Merzouki

Director & COO

Dr. Merzouki is an accomplished scientist with over 20 years of experience in virology and immunology. Dr. Merzouki obtained his Ph.D. in Virology and Immunology from Institut Armand-Frappier in Quebec and received his post-doctoral training at the University of British Columbia and the BC Center for Excellence in HIV/AIDS research. He was appointed as a Director and Chief Operating Officer of Sunshine Biopharma in February 2015. Dr. Merzouki has over 30 publications and 70 communications in various, highly respected scientific journals in the field of cellular and molecular biology. Prior to joining Sunshine, Dr. Merzouki worked at the Institute of Biomedical Engineering in the Department of Chemical Engineering at Ecole Polytechnique de Montreal, where he taught and acted as a senior scientist involved in the research and development of plasmid and siRNA-based therapies. He also worked in the area of gene therapy where he performed several preclinical studies for pharmaceutical companies involving the use of adenoviral vectors for cancer therapy and plasmid vectors for the treatment of peripheral arterial occlusions. Dr. Merzouki also has extensive expertise in the design of expression vectors, and production and purification of recombinant proteins. He developed technologies for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. In addition to his academic expertise, Dr. Merzouki has a strong worldwide network of business and financial relationships.

Press Releases

November 6, 2019
Sunshine Biopharma Receives Health Canada Approval for Essential Calcium-Vitamin DTM Supplement

October 17, 2019
SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER

September 3, 2019
Sunshine Biopharma Receives Vegan Certification for Essential 9™ Amino Acids Supplement

May 28, 2019
In Addition to Essential 9™, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca

May 16, 2019
Sunshine Biopharma Announces that Essential 9™ is Now Available in the United States on Amazon.com

March 12, 2019
Sunshine Biopharma Announces That ESSENTIAL 9™ Is Now Available On amazon.ca

February 4, 2019
Sunshine Biopharma Receives Notice Of Allowance For A New Patent Application Extending Protection Of Adva-27a Anticancer Drug Until 2033

December 17, 2018
Sunshine Biopharma Receives Health Canada Approval for Essential 9™, The Company's First Over The Counter Essential Micronutrient

December 12, 2018
Sunshine Biopharma Signs an Agreement With Crocus Laboratories for Manufacturing of Adva-27a Anticancer Drug

September 14, 2018
Sunshine Biopharma Announces $10 Million Equity Financing

August 16, 2018
Sunshine Biopharma Signs A Service Agreement With Utah Based Quintessential Biosciences Inc.

June 18, 2018
Sunshine Biopharma Launches Microbiology Testing Service

May 10, 2018
Sunshine Biopharma Annouces Extension Of The Term Of Its Brokered Up To $10 Million Private Placement Financing

January 4, 2018
Sunshine Biopharma Completes the Acquisition of Atlas Pharma